Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, and acellular pertussis vaccine (adsorbed, reduced antigen content)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Boostrix is a reduced-antigen, acellular pertussis-containing vaccine (Tdap) developed by GSK. It is indicated for booster immunization against diphtheria, tetanus, and pertussis in individuals aged 10 years and older. The vaccine contains five active antigenic components: diphtheria toxoid, tetanus toxoid, and three pertussis antigens (pertussis toxoid, filamentous haemagglutinin, and pertactin). It is formulated with a lower concentration of diphtheria and pertussis antigens compared to pediatric DTaP vaccines (such as Infanrix) to minimize reactogenicity in adolescents and adults while maintaining protective immunogenicity. The vaccine is administered as a single intramuscular injection and is often used as a decennial booster or during pregnancy to provide passive immunity to neonates.
- Other names
- TdapdTpadiphtheria toxoid + tetanus toxoid + pertussis toxoid + filamentous haemagglutinin + pertactin
02
Targets
PRN (Pertactin)Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria, tetanus, and acellular pertussis vaccine (adsorbed, reduced antigen content).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, and acellular pertussis vaccine (adsorbed, reduced antigen content).